Quotient Clinical has entered into a collaboration with Pulmatrix, Inc. to support the development of PUR0200, a new bronchodilator therapy for the treatment of COPD. It’s the first small molecule product from Pulmatrix’s inhaled iSPERSE technology platform.
 
Quotient will employ its RapidFACT (Rapid Formulation development And Clinical Testing) service to manufacture the spray dried PUR0200 product to support the Phase Ib trial in COPD patients. This capability allows within-protocol adjustment of the formulation composition for any arising safety, pharmacokinetic and pharmacodynamic data to optimize performance. The study will take place at Quotient’s site in Nottingham, UK.
 
Mark Egerton, managing director of Quotient Clinical, said,  “We are delighted that Pulmatrix has chosen to utilize our RapidFACT service to support the development PUR0200. We have proven that RapidFACT can shorten timelines and reduce costs in early development, which ultimately contributes to enhancing R&D productivity. This particular study also demonstrates our ability to manufacture and supply drug product in real time to other clinical centers of excellence that specialize in specific disease indications and endpoints.”